Annual Report

Overview

The report presents 2024 as a year of preparation for Cinclus Pharma's Phase III eGERD program, following the June Nasdaq Stockholm listing and the first Chinese marketing authorization for linaprazan glurate. Group net sales were 4,580 TSEK, generated by development and regulatory milestones. Its sustainability discussion centers on public-health impact, patient access, employee wellbeing and the further development of sustainability work.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Language: English
Pages
File size
Restatement: Disclosed

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services